Clinical Trials Sponsored by Claudio Gobbi

Total 294 results

Claudio Gobbi
Ospedale Civico, Lugano

Completed

Natalizumab De-escalation With Interferon Beta-1b

Relapsing-remitting Multiple Sclerosis

Switzerland
Claudio Gobbi
Bayer

Terminated

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Switzerland
Claudio Gobbi
Merck AG Switzerland

Active, not recruiting

Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

Multiple Sclerosis

Switzerland
Claudio Gobbi
Swiss Multiple Sclerosis Society

Completed

Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino

Multiple Sclerosis

Switzerland
Claudio Gobbi
Ente Ospedaliero Cantonale, Ticino, Switzerland

Terminated

Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis

Multiple Sclerosis

Switzerland
Claudio Castanos

Completed

Efficacy and Safety of Azithromycin in Patients With Bronchiolitis Obliterans

Bronchiolitis Obliterans
Claudio Nigg
University of Bern

Completed

A Study to Promote Physical Activity Motivation in Cardiovascular Disease Patients (iPAL)

Cardiovascular Diseases

Switzerland
Claudia Aristizábal
Sanitas University

Completed

Non-immersive Virtual Reality for Pediatric Pain Management

Procedural Pain

Colombia
Claudio Mendes Pannuti

Completed

Effect of Smoking Cessation on Clinical and Microbiological Outcomes of the Non-surgical Periodontal Therapy (EsCAPE2)

Periodontitis
Institut Claudius Regaud

Recruiting

Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae (LAMBEAU STEPA)

Head and Neck Cancer | Oropharynx Cancer | Oral Cavity Cancer

France
Institut Claudius Regaud

Recruiting

Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy (BLAD-RAD01)

Urothelial Bladder Cancer

France
Institut Claudius Regaud

Recruiting

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy (MINER)

Solid Cancers

France
Institut Claudius Regaud

Recruiting

Prospective Melanoma Database

Melanoma

France
Institut Claudius Regaud

Active, not recruiting

Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm (COCABIO000)

Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm

France
Institut Claudius Regaud

Completed

Evaluation of an Organized Consultation "Return Home" of Patients With a Cancer (CREDO) (CREDO)

METASTATIC CANCER

France
Institut Claudius Regaud

Completed

Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer. (CARMMYC)

Breast Cancer

France
Institut Claudius Regaud

Completed

Study Evaluating Treatment Adherence in Patients Treated With Oral Targeted Therapy in Oncology Supported by a Dedicated and Coordinated Follow-up Compared to Standard Follow-up. (ADHESIPH)

Metastatic Solid Tumor

France
Institut Claudius Regaud

Completed

A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection. (MEDIRAD)

Differentiated Thyroid Cancer

France
Institut Claudius Regaud

Withdrawn

Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA) (PROSTIRNA)

Prostatic Cancer, Castration-Resistant

France
Institut Claudius Regaud

Unknown

Evaluation of the Adhesion to the GENEPY Network (GENEPY)

Hereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome | Hereditary Colorectal Endometrial Cancer Syndrome

France
Institut Claudius Regaud

Terminated

Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella (GRATSEC)

Breast Cancer

France
Institut Claudius Regaud

Terminated

Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma

Soft Tissue Sarcoma of Members

France
Institut Claudius Regaud

Completed

Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment (EVAL'COACH)

Solid Tumors

France
Institut Claudius Regaud

Completed

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer (PHACS)

Hormono-depending Adjuvant Breast Cancer

France
Institut Claudius Regaud

Completed

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

Genital Neoplasms, Male

France
Institut Claudius Regaud

Completed

Determination of Carboplatin's Optimal Plasmatic Exposure

Neoplasms

France
Institut Claudius Regaud

Completed

Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.

Breast Neoplasms

France
Claudia Guerrieri

Enrolling by invitation

Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer (SURE-02)

Muscle-invasive Urothelial Carcinoma of the Bladder

Italy
Claudia Spies

Completed

Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care

Sedation in Intensive Care Unit Patients

Germany
Claudia Spies

Completed

Clock Genes in Patients With Refractory Septic Shock (SeptiClock) - Pilot Study

Septic Shock

Germany
Claudia Spies

Completed

Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Abdominal Surgery (Neuprodex)

Delirium | Postoperative Cognitive Deficit (POCD)

Germany
Claudia Spies

Completed

Optimization of the Anesthetic Regimen Using the SmartPilot® System and Influence on Different Outcome Parameters - a Pilot Study.

Postoperative Cognitive Disturbances

Germany
Claudia Lorenz-Schlüter

Terminated

Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin (MyoPac)

Metastatic Breast Cancer

Germany
Claudia Spies

Terminated

Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery

Post-operative Pain

Germany
Institut Claudius Regaud

Recruiting

Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene. (LUCID)

DDX41 Gene Mutation

France
Institut Claudius Regaud

Recruiting

A Study to Evaluate Pre- or Post-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa. (HYPOSARC)

Soft Tissue Sarcoma

France
Institut Claudius Regaud

Recruiting

Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients (SLEEP_CTC)

Lung Cancer

France
Institut Claudius Regaud

Recruiting

Evaluation of the Interest of a Video-assisted Remote Speech Therapy Consultation in Patients With ORL Cancer (TELE ORTHOPHONIE)

ORL Cancer

France
Institut Claudius Regaud

Recruiting

Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain. (TEC-ORL)

Head and Neck Cancer

France
Institut Claudius Regaud

Recruiting

Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma (EPOP-SARCOMA)

Sarcoma

France
Institut Claudius Regaud

Recruiting

Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy (HYPNOMUSE)

Solid Tumor

France
Institut Claudius Regaud

Recruiting

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group (MIRAS)

Soft Tissue Sarcoma | Perivascular Epithelioid Cell Neoplasms | Epithelioid Sarcoma | Alveolar Soft Part Sarcoma | Desmoplastic Small Round Cell Tumor | Clear Cell Sarcoma | Sclerosing Epithelioid Fibrosarcoma | Low Grade Fibromyxoid Sarcoma | Malignant Solitary Fibrous Tumors | Epithelioid Hemangioendothelioma

France
Institut Claudius Regaud

Recruiting

Platino-resistance in Ovarian Cancer (PlatinOv)

Epithelial Ovarian Cancer

France
Institut Claudius Regaud

Completed

TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (TICIMEL)

Melanoma

France
Institut Claudius Regaud

Completed

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival (METAL3)

Metastatic Breast Cancer Starting a Third Line Chemotherapy

France
Institut Claudius Regaud

Completed

CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma (OVASARC)

Ovarian Adenocarcinoma

France
Institut Claudius Regaud

Completed

Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC (MIMOSA)

Triple Negative Breast Cancer

France
Institut Claudius Regaud

Completed

E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer. (EPOPEE)

Breast Cancer

France
Institut Claudius Regaud

Completed

Optimization of the Patient Care Pathway in Immuno-oncology (OPTIMMUNO)

Melanoma

France
Institut Claudius Regaud

Completed

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis (TICE)

Germ Cell Tumors

France

3

Subscribe